BioSpace News Archive

CohBar, Inc. (NASDAQ: CWBR), a clinical stage biotechnology company developing mitochondria based therapeutics to treat chronic diseases and extend healthy lifespan, today announced the appointment of Joseph J. Sarret, M.D., J.D. as Chief Executive Officer and Director, effective May 3, 2021.

Cryoport, Inc. (NASDAQ: CYRX) (“Cryoport” or the “Company”), a global leader in temperature-controlled supply chain solutions for the life sciences industry, today announced that the Company will report financial results for the first quarter ended March 31, 2021 on Tuesday, May 4, 2021 after U.S. markets close.

Relmada Therapeutics, Inc. (Nasdaq: RLMD), a late-stage biotechnology company addressing diseases of the central nervous system (CNS), today announced that data related to REL-1017, the company’s lead product candidate, will be presented in a poster at the American Society for Pharmacology and Experimental Therapeutics (ASPET) Annual Meeting

Medicx Health, today, announced the successful completion of its 2021 Risk Re-Identification Determination (RRID) Assessment, which is an evaluation of re-identification risks for Medicx’s patient audience data and use in targeted advertising.

A new national survey released today by the Collaborative Institutional Training Initiative (CITI Program), a division of BRANY (Biomedical Research Alliance of New York), reveals progress towards a return to in-person learning and research, against a backdrop of persisting concerns including access to vaccines and new COVID-19 variants.

Impact Biosystems, the Boston-based company that develops adaptive hardware and software services in the sports recovery space, closed $4.5m in new funding, co-led by Will Ventures and NextView Ventures.

Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH), a global leader in musculoskeletal healthcare, today announced that President and CEO Bryan Hanson and Executive Vice President and CFO Suky Upadhyay will be presenting at BofA Securities 2021 Virtual Health Care Conference on Tuesday, May 11, 2021 , at 12:30 p.m. Eastern Time .

Valeo Pharma Inc . (CSE: VPH) a Canadian pharmaceutical company, announced today that it has upsized and closed a $6.645 million non-brokered private placement of unsecured non-convertible debenture units

Berkshire Biomedical, LLC (“Berkshire” or “the Company”), a privately-held digital health company developing a revolutionary virtual care prescription drug delivery and management system only for the Intended User, today announced the appointment of John E. Timberlake as President and Chief Executive Officer.

- First patient for Phase I/II SUNRISE trial expected to be enrolled by mid-year 2021 - Company also entered into strategic collaboration with CANbridge Pharmaceuticals and research partnership with Daiichi Sankyo